Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetration
Source abstract
Abstract
Poor tumour penetration became a major challenge for the use of nanoparticles in anticancer therapy. To further enhance the tumour penetration efficiency, we developed a tumour-microenvironment-responsive multistage drug delivery system which was formed layer by layer via electrostatic interaction with cationic drug-loaded nanoparticles, hyaluronidase (HAase) and iRGD-modified gelatin (G-iRGD). The drug-loaded nanoparticles were formed by self-assembling mPEG-PDPA-PG and encapsulation with epirubicin (EPI). Due to the protonation of tertiary amine groups of PDPA segment in acid environment, mPEG-PDPA-PG could enhance the lysosomal escape and the intracellular release of EPI. This NPs/HAase/G-iRGD delivery system showed great biocompatibility in vitro, confirmed by MTT method. In vitro spherical tumour model penetration and in vivo tumour permeability investigation showed HAase coated NPs-EPI (NPs-EPI/HAase) could significantly enhance its penetrating efficiency. The NPs-EPI/HAase could assist in breaking down the hyaluronic acid (HA), which was a key component of extracellular matrix and thereby improving mass transport within the solid tumours. The flow cytometry studies showed that G-iRGD coated NPs-EPI (NPs-EPI/G-iRGD) was more easily taken up by HepG2 cells than gelatin coated NPs-EPI (NPs-EPI/G), which revealed the active targeting ability of iRGD. The results proved that this NPs/HAase/G-iRGD delivery system showed promising potential in enhancing tumour penetration efficiency.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao, China;
Department of Oncology, No. 2 Affiliated Hospital of Qingdao University, Qingdao, China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Shandong Province
References (44)
Show source-provided references
1. 10.18632/oncotarget.569210.18632/oncotarget.5692 ↗
2. 10.2147/IJN.S13003710.2147/IJN.S130037 ↗
3. 10.7150/thno.1174210.7150/thno.11742 ↗
4. 10.1021/bm401526d10.1021/bm401526d ↗
5. 10.1016/j.actbio.2015.12.00210.1016/j.actbio.2015.12.002 ↗
6. 10.1016/j.msec.2016.10.01810.1016/j.msec.2016.10.018 ↗
7. 10.1073/pnas.101838210810.1073/pnas.1018382108 ↗
8. 10.3109/21691401.2014.88340210.3109/21691401.2014.883402 ↗
9. 10.1016/j.msec.2017.04.09810.1016/j.msec.2017.04.098 ↗
10. 10.1016/j.msec.2017.05.05410.1016/j.msec.2017.05.054 ↗
11. 10.1016/j.msec.2017.04.11610.1016/j.msec.2017.04.116 ↗
12. 10.7150/thno.1668410.7150/thno.16684 ↗
13. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
14. 10.1021/acs.biomac.7b0006810.1021/acs.biomac.7b00068 ↗
15. 10.1016/j.biomaterials.2016.09.00110.1016/j.biomaterials.2016.09.001 ↗
16. Kandela I · ELIFE · 2017 · 6 · 110.7554/eLife.17044 ↗
17. 10.1016/j.ijpharm.2015.11.02510.1016/j.ijpharm.2015.11.025 ↗
18. 10.1016/j.biomaterials.2015.05.00610.1016/j.biomaterials.2015.05.006 ↗
19. 10.1016/j.msec.2013.12.02110.1016/j.msec.2013.12.021 ↗
20. 10.3109/21691401.2014.96274710.3109/21691401.2014.962747 ↗
21. 10.1016/j.phrs.2017.05.00410.1016/j.phrs.2017.05.004 ↗
22. 10.2174/138920021766616063020360010.2174/1389200217666160630203600 ↗
23. 10.1021/acs.molpharmaceut.7b0047510.1021/acs.molpharmaceut.7b00475 ↗
24. 10.1016/j.msec.2017.03.25910.1016/j.msec.2017.03.259 ↗
25. 10.1166/jbn.2015.214510.1166/jbn.2015.2145 ↗
26. 10.1016/j.biomaterials.2013.01.04310.1016/j.biomaterials.2013.01.043 ↗
27. 10.7150/thno.1353210.7150/thno.13532 ↗
28. 10.1016/j.biomaterials.2018.03.04610.1016/j.biomaterials.2018.03.046 ↗
29. 10.1021/acsnano.6b0507010.1021/acsnano.6b05070 ↗
30. 10.1016/j.jconrel.2018.04.00510.1016/j.jconrel.2018.04.005 ↗
31. 10.1039/C5NR01408E10.1039/C5NR01408E ↗
32. 10.1021/acs.nanolett.6b0082010.1021/acs.nanolett.6b00820 ↗
33. 10.1021/acs.nanolett.6b0006810.1021/acs.nanolett.6b00068 ↗
34. 10.1016/B978-0-12-391860-4.00006-910.1016/B978-0-12-391860-4.00006-9 ↗
35. 10.1007/978-3-319-16555-4_910.1007/978-3-319-16555-4_9 ↗
36. 10.1002/ange.20035279110.1002/ange.200352791 ↗
37. 10.1021/ja044205+10.1021/ja044205+ ↗
38. 10.1021/acs.nanolett.6b0291510.1021/acs.nanolett.6b02915 ↗
39. 10.1021/acs.biomac.7b0093110.1021/acs.biomac.7b00931 ↗
40. 10.1080/21691401.2017.130721510.1080/21691401.2017.1307215 ↗
41. 10.1016/j.biotechadv.2013.11.00910.1016/j.biotechadv.2013.11.009 ↗
42. 10.1016/j.msec.2017.03.26310.1016/j.msec.2017.03.263 ↗
43. 10.1007/s13233-012-0059-510.1007/s13233-012-0059-5 ↗
44. 10.1021/acsami.5b0939110.1021/acsami.5b09391 ↗